Current and Future Therapeutic Strategies for Multiple Myeloma
  • CME

In this Interactive Virtual Presentation, gain case-based insights in incorporating new findings and novel agents into the treatment paradigm for patients with multiple myeloma.
Peter M. Voorhees, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: June 23, 2020 Expiration: June 22, 2021
Multimedia Current and Future Therapeutic Strategies for Multiple Myeloma
This program is divided into short segments which you can review from the Activity landing page.
Smoldering Multiple Myeloma (19 minutes)
Expert discussion of risk stratification for patients with smoldering myeloma and new data on initial management options for patients with high-risk smoldering multiple myeloma.
Launch Smoldering Multiple Myeloma (19 minutes)
Newly Diagnosed Active Multiple Myeloma (41 minutes)
Expert discussion of current optimal treatment and emerging agents for newly diagnosed active multiple myeloma.
Launch Newly Diagnosed Active Multiple Myeloma (41 minutes)
Relapsed/Refractory Multiple Myeloma (56 minutes)
Expert discussion of therapy for patients with relapsed/refractory multiple myeloma, including immunotherapy combinations and novel agents.
Launch Relapsed/Refractory Multiple Myeloma (56 minutes)

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan management of patients based on an accurate diagnosis of monoclonal gammopathy of undetermined significance, smoldering MM, or active MM
  • Create individualized treatment strategies for patients with newly diagnosed MM through consideration of the available clinical data as well as risk assessment, age, comorbidities, and patient preferences
  • Evaluate the efficacy and safety evidence of combination regimens to individualize therapeutic strategies for patients with MM at first relapse
  • Plan appropriate treatment strategies using all available agents and classes to provide efficacious combination therapies to heavily pretreated patients with relapsed/refractory MM
  • Employ novel agents and clinical trial participation as part of clinical care strategies for MM

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AbbVie
Amgen
Celgene Corporation
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Oncopeptides

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Peter M. Voorhees, MD

Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute
Charlotte, North Carolina

Peter M. Voorhees, MD, has no relevant conflicts of interest to report.

Staff

Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has reported that his spouse/partner has ownership interest (stock) in AstraZeneca.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

The Annenberg planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with MM and also patients with MM.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the care of their patients with myeloma.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2020, through June 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Free video from Clinical Care Options featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Michael R. Bishop, MD
Program Director
Daniel J. DeAngelo, MD, PhD Noopur Raje, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.5 Medical Knowledge MOC point(s) Released: August 14, 2020 Expired: August 13, 2021

Dr. Jacqueline Barrientos shares her experiences managing patients with CLL during the COVID-19 pandemic in NYC and offers recommendations, from CCO

Jacqueline Barrientos, MD, MS Released: August 11, 2020

Downloadable summary slideset with a quick summary of the current treatment algorithm for CLL, from Clinical Care Options.

Farrukh T. Awan, MD Ian W. Flinn, MD, PhD Released: August 5, 2020

John M. Burke, MD Released: August 4, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?